Harmony Head-to-Head Study for Advanced Melanoma
This study is investigating fianlimab combined with cemiplimab for adults with advanced or metastatic melanoma (a type of skin cancer). We want to see how safe and effective this combination is compared to relatlimab plus nivolumab (Opdualag™), which is already approved for melanoma. The study will also look at potential side effects and how the drugs move through your body. You may be able to join if you are 18 or older, have advanced melanoma that hasn't been treated with prior systemic therapy, and have measurable disease. The main goal is to see how many participants respond to the treatment.
- Study design
- This study plans to enroll 560 participants. It is an interventional study comparing two different drug combinations.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 72 months to assess objective response rate.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
At a glance
Conditions
Where it's being run
111 sites across 41 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on blinded independent central review (BICR)Up to 72 months